The following stories appear in full on today's Vidyya Medical News Service Web site.
The electronic revolution that is currently widening the information gap will eventually narrow, and perhaps even abolish, the gap. It will always be expensive and slow to send journals to the developing world. The marginal cost of sending the paper editions of the Lancet or the BMJ every week for a year to Africa is well over £50, and they can take months to arrive. In contrast, the marginal cost of giving access is lower. What is more, those in resource poor countries can access electronic journals at exactly the same time as those in the developed world. The ecology of information will change dramatically in the next 20 years in ways that we cannot fully understand. There seems, however, every chance that information exchange among those interested in health should improve dramatically, leading ultimately to an improvement in health itself. Read an editorial by individuals that are calling on major publishers to provide information at lower or free cost to the developing world.
PubMed Central is a barrier-free NIH repository for peer-reviewed primary research reports in the life sciences, which began accepting journal articles in January 2000. Get more information on PubMed Central, including how to access the site, in today's issue of Vidyya.
There are many textbooks on the Web and many free sites, but sites like E-medicine, truly capture the spirit of Internet medical information. What sets this site apart from other medical information databases is the cutting-edge nature of the information available. The doctors who author the text available on the E-medicine site log-on to the site and update their chapters at any time, day or night. This means that E-medicine delivers the most contemporary medical information in an accessible medium with no cost to users. Revenue for E-Medicine is from advertisers such as Glaxo-Wellcome.
Roche Laboratories is informing health practitioners of important safety-related changes to the prescribing information concerning the use of Xeloda in patients with renal impairment at baseline. A copy of the complete revised labeling is included in this issue of Vidyya.
As always, we hope you enjoy the issue.